BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28868954)

  • 21. Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant
    Deng AL; Kim YR; Lichtenstein EA; O'Connor OA; Deng C
    Haematologica; 2017 Jul; 102(7):e275-e277. PubMed ID: 28341730
    [No Abstract]   [Full Text] [Related]  

  • 22. Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.
    Gurth M; Bernard V; Bernd HW; Schemme J; Thorns C
    Leuk Lymphoma; 2017 Apr; 58(4):979-981. PubMed ID: 27687087
    [No Abstract]   [Full Text] [Related]  

  • 23. [Combination of zanubrutinib and rituximab in the treatment of primary cutaneous diffuse large B-cell lymphoma leg type with CD79B and MYD88 mutations: a case report].
    Zhong GC; Yu XN; Li J; Chen CY
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):258. PubMed ID: 37356991
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.
    Gebauer N; Gebauer J; Hardel TT; Bernard V; Biersack H; Lehnert H; Rades D; Feller AC; Thorns C
    Leuk Lymphoma; 2015 Apr; 56(4):1100-6. PubMed ID: 25030036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
    Lee JH; Jeong H; Choi JW; Oh H; Kim YS
    Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features.
    Liu Y; Yu K; Li M; Zeng K; Wei J; Li X; Liu Y; Zhao D; Fan L; Yu Z; Wang Y; Li Z; Zhang W; Bai Q; Yan Q; Guo Y; Wang Z; Guo S
    Hum Pathol; 2017 Jun; 64():213-221. PubMed ID: 28438623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 29. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
    Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.
    Xue X; Huang W; Qiu T; Guo L; Ying J; Lv N
    BMC Cancer; 2020 Aug; 20(1):816. PubMed ID: 32854650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
    Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
    J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
    Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
    Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.
    Nichele I; Zamò A; Bertolaso A; Bifari F; Tinelli M; Franchini M; Stradoni R; Aprili F; Pizzolo G; Krampera M
    PLoS One; 2012; 7(12):e52811. PubMed ID: 23285191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
    Ducharme O; Beylot-Barry M; Pham-Ledard A; Bohers E; Viailly PJ; Bandres T; Faur N; Frison E; Vergier B; Jardin F; Merlio JP; Gros A
    J Invest Dermatol; 2019 Nov; 139(11):2334-2342.e8. PubMed ID: 31150604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
    Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
    Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
    Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma.
    Menguy S; Gros A; Pham-Ledard A; Battistella M; Ortonne N; Comoz F; Balme B; Szablewski V; Lamant L; Carlotti A; Lorton MH; de Muret A; Le Gall F; Franck F; Croue A; Cappellen D; Beylot-Barry M; Merlio JP; Vergier B
    J Invest Dermatol; 2016 Aug; 136(8):1741-1744. PubMed ID: 27189828
    [No Abstract]   [Full Text] [Related]  

  • 38. From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.
    Jiménez C; Alonso-Álvarez S; Alcoceba M; Ordóñez GR; García-Álvarez M; Prieto-Conde MI; Chillón MC; Balanzategui A; Corral R; Marín LA; Gutiérrez NC; Puig N; Sarasquete ME; González M; García-Sanz R
    Blood Cancer J; 2017 Aug; 7(8):e591. PubMed ID: 28841204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic cooperation and crosstalk between
    Wang JQ; Jeelall YS; Humburg P; Batchelor EL; Kaya SM; Yoo HM; Goodnow CC; Horikawa K
    J Exp Med; 2017 Sep; 214(9):2759-2776. PubMed ID: 28701369
    [No Abstract]   [Full Text] [Related]  

  • 40. "Quadruple-hit" primary testicular diffuse large B-cell lymphoma with MYD88 L265P mutation, IGH::MYC, and IRF4- and BCL6-rearrangements.
    Bruehl FK; Ketterling RP; Rimsza LM; Santos EF; McPhail ED
    J Hematop; 2023 Sep; 16(3):161-165. PubMed ID: 38175404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.